Hematology/Oncology

Top Story

Risk protocol identifies patients with cancer not allergic to carboplatin, oxaliplatin

August 28, 2015

Patients with cancer who had a history of presumed carboplatin- and oxaliplatin-induced hypersensitivity reaction did not appear allergic to the chemotherapy drugs after skin prick tests, according to retrospective study results.

The risk-stratification protocol appeared to safely identify patients without allergic reaction to the drugs, allowing them to return to an outpatient setting for further treatment without desensitization.

In the Journals

Intestinal obstruction a long-term risk for survivors of childhood cancer

August 28, 2015
Survivors of childhood cancer face a long-term risk for intestinal obstruction requiring surgery as a result of their treatment, according to findings from the Childhood…
Erica L. Mayer, MD, MPH In the Journals

Aromatase inhibitors improve recurrence rates, survival in early breast cancer

August 28, 2015
The use of an aromatase inhibitor reduced breast cancer recurrence rates approximately 30% compared with tamoxifen, according to the results of a meta-analysis.Further…
In the Journals

Researchers develop value-based framework for cancer drug pricing

August 27, 2015
Researchers have developed a framework for establishing value-based pricing for new oncology drugs that are entering the U.S. market.“Cancer drug prices have been…
In the Journals

Overall global health improving, years lived with disability rising

August 27, 2015
Around the world, the average life expectancy increased by more than 6 years between 1990 and 2013; however, individuals are spending more years than ever living with…
More News Headlines »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
Tailored Therapies for Myelodysplastic Syndromes

Tailored Therapies for Myelodysplastic Syndromes

This activity is supported by an educational grant from Celgene Corporation.

Myelodysplastic syndromes (MDS) represent a group of myeloid clonal hemopathies with heterogeneous clinical…
More »
morganatic-roan
morganatic-roan